Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

Fig. 2

Physician-reported reasons for treatment choice: NHA or Chemotherapy [± ADT] vs ADT alone. Note: All treatments were ± ADT, except ADT alone. *Significant difference observed between treatment groups (p < 0.0167). ADT androgen deprivation therapy, AE adverse event, CNS central nervous system, NHA novel hormonal agents (abiraterone, enzalutamide, apalutamide, darolutamide), OS overall survival, PFS progression free survival, QoL Quality of Life

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us